Market closedNon-fractional
Achieve Life Sciences/ACHV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Achieve Life Sciences
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Ticker
ACHV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Vancouver, Canada
Employees
22
Website
www.achievelifesciences.com
ACHV Metrics
BasicAdvanced
$156M
Market cap
-
P/E ratio
-$1.26
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$156M
Beta
1.26
Financial strength
Current ratio
3.291
Quick ratio
3.227
Total debt to equity
34.766
Interest coverage (TTM)
-7.97%
Management effectiveness
Return on assets (TTM)
-33.93%
Return on equity (TTM)
-109.49%
Valuation
Price to book
3.18
Price to tangible book (TTM)
3.32
Price to free cash flow (TTM)
-4.566
Growth
Earnings per share change (TTM)
-63.32%
3-year earnings per share growth
-36.86%
What the Analysts think about ACHV
Analyst Ratings
Majority rating from 7 analysts.
ACHV Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$6.4M
18.52%
Profit margin
0.00%
NaN%
ACHV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.43
-$0.34
-$0.26
-$0.26
-
Expected
-$0.42
-$0.38
-$0.31
-$0.24
-$0.23
Surprise
2.03%
-10.19%
-17.27%
6.56%
-
ACHV News
AllArticlesVideos
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
Seeking Alpha·5 days ago
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
GlobeNewsWire·2 months ago
Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Achieve Life Sciences stock?
Achieve Life Sciences (ACHV) has a market cap of $156M as of July 06, 2024.
What is the P/E ratio for Achieve Life Sciences stock?
The price to earnings (P/E) ratio for Achieve Life Sciences (ACHV) stock is 0 as of July 06, 2024.
Does Achieve Life Sciences stock pay dividends?
No, Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Achieve Life Sciences dividend payment date?
Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders.
What is the beta indicator for Achieve Life Sciences?
Achieve Life Sciences (ACHV) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Achieve Life Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.